An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) appoints William C. Fairey, former Chief Commercial Officer at MyoKardia, to its Board of Directors. Mr. Fairey brings over 30 years of experience in commercial and medical operations in the biotechnology and pharmaceutical industry. His expertise in rare diseases and product launches will support KalVista's focus on the FDA submission, potential approval, and commercial launch of sebetralstat, a treatment for hereditary angioedema.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) ha nominato William C. Fairey, ex Direttore Commerciale di MyoKardia, nel suo Consiglio di Amministrazione. Il Sig. Fairey apporta oltre 30 anni di esperienza nelle operazioni commerciali e mediche nell'industria biotecnologica e farmaceutica. La sua competenza nelle malattie rare e nei lanci di prodotti supporterà l'attenzione di KalVista sulla presentazione all'FDA, l'eventuale approvazione e il lancio commerciale di sebetralstat, un trattamento per l'angioedema ereditario.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) ha incorporado a William C. Fairey, ex Director Comercial en MyoKardia, a su Junta Directiva. El Sr. Fairey trae consigo más de 30 años de experiencia en operaciones comerciales y médicas en la industria biotecnológica y farmacéutica. Su pericia en enfermedades raras y lanzamientos de productos contribuirá al enfoque de KalVista en la presentación ante la FDA, la posible aprobación y el lanzamiento comercial de sebetralstat, un tratamiento para el angioedema hereditario.
KalVista Pharmaceuticals, Inc. (나스닥: KALV)는 MyoKardia의 전 최고 상업 책임자인 윌리엄 C. 페리를 이사회에 임명하였습니다. 페리 씨는 생명공학 및 제약 산업에서의 상업적 및 의료적 운영 분야에서 30년 이상의 경험을 가지고 있습니다. 그의 희귀 질환 및 제품 출시 전문 지식은 세베트랄스타트의 FDA 제출, 잠재적 승인 및 상업적 출시에 대한 KalVista의 초점을 지원할 것입니다.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) a nommé William C. Fairey, ancien Directeur Commercial chez MyoKardia, à son Conseil d'Administration. M. Fairey apporte plus de 30 ans d'expérience dans les opérations commerciales et médicales dans l'industrie biotechnologique et pharmaceutique. Son expertise dans les maladies rares et les lancements de produits soutiendra l'objectif de KalVista concernant la soumission à la FDA, l'approbation potentielle et le lancement commercial de sebetralstat, un traitement pour l'angioedème héréditaire.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) hat William C. Fairey, ehemaliger Chief Commercial Officer bei MyoKardia, in seinen Vorstand berufen. Herr Fairey bringt mehr als 30 Jahre Erfahrung in kommerziellen und medizinischen Operationen in der Biotechnologie- und Pharmaindustrie mit. Seine Expertise in seltenen Krankheiten und Produktstarts wird KalVista bei der Einreichung bei der FDA, möglichen Zulassung und kommerziellen Einführung von Sebetralstat, einer Behandlung für hereditäres Angioödem, unterstützen.
Positive
None.
Negative
None.
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that William C. Fairey has been appointed to the Company’s Board of Directors, effective immediately. Mr. Fairey was most recently the Chief Commercial Officer at MyoKardia, Inc., a clinical stage biopharmaceutical company, and is a business leader with significant experience building markets and launching novel therapeutics to treat specialty and rare/orphan diseases.
“We welcome Bill to our Board of Directors,” said Ben Palleiko, CEO of KalVista. “His experience in commercial and medical strategy, operations and product launches within the rare disease space will be invaluable to us as we continue our evolution into a commercial organization and focus on the FDA submission, potential approval and commercial launch of sebetralstat.”
“I’m excited to join KalVista’s board on the cusp of such a significant milestone as the planned FDA filing, and I look forward to helping advance the commercialization of sebetralstat,” said Mr. Fairey. “I believe KalVista has the opportunity to change the treatment paradigm in the hereditary angioedema space by delivering an efficacious and well-tolerated, oral on-demand treatment to the people living with this debilitating disease.”
Mr. Fairey has more than 30 years of experience in commercial and medical operations in the biotechnology and pharmaceutical industry, including shaping markets, developing products, determining global commercial/medical strategies, and leading cross-functional teams in delivering successful new product launches. Prior to MyoKardia, he served as Chief Operating Officer at ChemoCentryx, Inc. and held several positions of increasing responsibility at Actelion Pharmaceuticals, including serving as President for its US division, Vice President of the Asia Pacific Region, and President of Actelion Canada. He has also held several senior business, sales and market access roles at the Parke-Davis division of Warner-Lambert and has previously served on several life science company boards. Mr. Fairey received his M.B.A. from St. Mary’s College of California and his B.S. from the University of Oregon.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. KalVista disclosed positive phase 3 data for the KONFIDENT trial for its oral, on-demand therapy sebetralstat in February 2024. The Company anticipates submitting a new drug application to the U.S. FDA for sebetralstat in the first half of 2024 and expects to file for approval in Europe and Japan later in 2024. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment for people living with HAE and other diseases.
For more information about KalVista, please visit www.kalvista.com.
Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and their results, our ability to obtain regulatory approvals for sebetralstat and other candidates in development, the success of any efforts to commercialize sebetralstat, the ability of sebetralstat and other candidates in development to treat HAE or other diseases, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2023, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Who has been appointed to KalVista Pharmaceuticals' Board of Directors?
William C. Fairey has been appointed to KalVista Pharmaceuticals' Board of Directors.
What is William C. Fairey's background?
William C. Fairey has over 30 years of experience in commercial and medical operations in the biotechnology and pharmaceutical industry. He was most recently the Chief Commercial Officer at MyoKardia, Inc.
What is the focus of KalVista Pharmaceuticals?
KalVista Pharmaceuticals is focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors.
What is the significance of the appointment of William C. Fairey?
The appointment of William C. Fairey brings valuable experience in rare diseases and product launches to support KalVista's focus on the FDA submission, potential approval, and commercial launch of sebetralstat.
kalvista is a clinical stage pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors.
